Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor.
ACY-1215
HDAC inhibitor
MITF
ML329
metastatic uveal melanoma
p-ERK
zebrafish xenografts
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Feb 2022
03 Feb 2022
Historique:
received:
16
12
2021
revised:
19
01
2022
accepted:
30
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
Metastatic uveal melanoma (MUM) is characterized by poor patient survival. Unfortunately, current treatment options demonstrate limited benefits. In this study, we evaluate the efficacy of ACY-1215, a histone deacetylase inhibitor (HDACi), to attenuate growth of primary ocular UM cell lines and, in particular, a liver MUM cell line in vitro and in vivo, and elucidate the underlying molecular mechanisms. A significant (
Identifiants
pubmed: 35159049
pii: cancers14030782
doi: 10.3390/cancers14030782
pmc: PMC8833954
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Irish Research Council - Enterprise Partnership Scheme 2020 Postdoctoral Fellowship
ID : EPSPD/2020/29
Organisme : TopMed10 - Marie Skłodowska-Curie Actions COFUND Programme
ID : 666010
Organisme : 3D NEONET Scheme: H2020 MSCA-RISE project
ID : 734907
Organisme : Crystal3 Scheme: H2020 MSCA-RISE project
ID : 101007931
Références
Case Rep Oncol Med. 2018 Apr 4;2018:4256365
pubmed: 29850322
Clin Cancer Res. 2008 Jan 1;14(1):115-22
pubmed: 18172260
J Enzyme Inhib Med Chem. 2021 Dec;36(1):34-47
pubmed: 33100043
Breast Cancer Res. 2015 Dec 08;17(1):149
pubmed: 26643555
Exp Dermatol. 2015 Jul;24(7):481-4
pubmed: 25866058
Ocul Oncol Pathol. 2019 Apr;5(3):195-204
pubmed: 31049328
Front Cell Dev Biol. 2021 Feb 11;9:616551
pubmed: 33644052
Cancer Cytopathol. 2015 Jul;123(7):394-400
pubmed: 25711993
Cancer Metastasis Rev. 2018 Sep;37(2-3):335-345
pubmed: 30094568
Bioinformatics. 2009 Apr 15;25(8):1091-3
pubmed: 19237447
Sci Rep. 2020 Oct 13;10(1):17051
pubmed: 33051548
Sci Rep. 2017 Sep 7;7(1):10909
pubmed: 28883623
Lab Invest. 2017 Jun;97(6):649-656
pubmed: 28263292
Eur J Cancer. 2018 Nov;103:41-51
pubmed: 30205280
Oncol Lett. 2021 Jan;21(1):64
pubmed: 33281975
Cell Death Dis. 2020 Jun 2;11(6):417
pubmed: 32488056
Int J Cancer. 2019 Aug 1;145(3):735-747
pubmed: 30694564
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
Onco Targets Ther. 2019 Apr 02;12:2409-2419
pubmed: 31118659
J Clin Invest. 2014 Jan;124(1):30-9
pubmed: 24382387
Front Cell Dev Biol. 2020 Aug 26;8:689
pubmed: 32984302
Oncogene. 2014 Sep 25;33(39):4724-34
pubmed: 24141786
J Biomed Biotechnol. 2011;2011:875824
pubmed: 21076528
Nat Rev Cancer. 2020 May;20(5):263-273
pubmed: 32251397
Invest Ophthalmol Vis Sci. 2019 Jun 3;60(7):2474-2480
pubmed: 31173078
J Invest Dermatol. 2015 Feb;135(2):352-358
pubmed: 25142731
Gynecol Oncol Rep. 2019 Aug 10;29:118-122
pubmed: 31467965
Nat Protoc. 2010 Dec;5(12):1911-8
pubmed: 21127485
Cancers (Basel). 2020 Sep 08;12(9):
pubmed: 32911759
J Investig Dermatol Symp Proc. 2001 Nov;6(1):99-104
pubmed: 11764295
Oncol Rep. 2017 Feb;37(2):1270-1276
pubmed: 28035401
Trends Mol Med. 2006 Sep;12(9):406-14
pubmed: 16899407
Bioinformatics. 2013 Mar 1;29(5):661-3
pubmed: 23325622
Nat Commun. 2021 Aug 27;12(1):5155
pubmed: 34453044
BMC Cancer. 2019 May 2;19(1):415
pubmed: 31046743
Drug Dev Res. 2021 Jun;82(4):598-604
pubmed: 33428788
Cell Death Dis. 2018 Jul 26;9(8):817
pubmed: 30050135
Sci Rep. 2020 Feb 26;10(1):3470
pubmed: 32103105
Ann Transl Med. 2019 Jan;7(1):2
pubmed: 30788349
Lancet Oncol. 2016 Nov;17(11):1569-1578
pubmed: 27646843
Oncogene. 2014 Sep 25;33(39):4722-3
pubmed: 24413085
J Biol Chem. 2018 Feb 9;293(6):1976-1993
pubmed: 29259132
Anticancer Res. 2018 Jul;38(7):3817-3824
pubmed: 29970501
Nature. 2009 Jan 29;457(7229):599-602
pubmed: 19078957
Sci Transl Med. 2019 Sep 11;11(509):
pubmed: 31511426
Arch Ophthalmol. 2002 Dec;120(12):1625-9
pubmed: 12470134
Invest Ophthalmol Vis Sci. 2011 Mar 02;52(3):1193-9
pubmed: 21051724
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
J Immunol Sci. 2018;2(3):59-68
pubmed: 30854521
J Clin Oncol. 2018 Apr 20;36(12):1232-1239
pubmed: 29528792
Tohoku J Exp Med. 2017;242(4):291-302
pubmed: 28794318
Invest Ophthalmol Vis Sci. 2014 Sep 23;55(10):6612-22
pubmed: 25249605
Cancer Chemother Pharmacol. 2017 Jun;79(6):1187-1193
pubmed: 28447210
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Int J Oncol. 2018 Aug;53(2):844-854
pubmed: 29749542
Invest Ophthalmol Vis Sci. 1991 Dec;32(13):3198-208
pubmed: 1748551
Oncologist. 2021 Mar;26(3):184-e366
pubmed: 33458921
Cancer J. 2012 Mar-Apr;18(2):148-52
pubmed: 22453016
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Br J Cancer. 2005 Jun 6;92(11):2032-8
pubmed: 15928660
Cancer Res. 1993 Sep 1;53(17):3976-85
pubmed: 8358726
Br J Ophthalmol. 1995 Feb;79(2):174-7
pubmed: 7696240
Clin Exp Metastasis. 1997 Sep;15(5):509-18
pubmed: 9247253
J Cell Biol. 2005 Jan 3;168(1):35-40
pubmed: 15623583
Exp Mol Med. 2016 Jan 15;48(1):e204
pubmed: 27534532
Oncogene. 2007 Aug 13;26(37):5468-76
pubmed: 17694087
J Biol Chem. 1999 Aug 13;274(33):22932-40
pubmed: 10438458
J Biol Chem. 2013 Nov 15;288(46):33156-70
pubmed: 24089523
Clin Cancer Res. 2021 Jan 1;27(1):28-33
pubmed: 33060121
J Skin Cancer. 2011;2011:730170
pubmed: 22046555
PLoS One. 2013 Sep 04;8(9):e73401
pubmed: 24023871
Exp Dermatol. 2010 Jul 1;19(7):617-27
pubmed: 20201954
Genes Dev. 2017 Apr 15;31(8):724-743
pubmed: 28512236
Nature. 2005 Jul 7;436(7047):117-22
pubmed: 16001072
Melanoma Res. 2017 Dec;27(6):591-595
pubmed: 29076951
Clin Ophthalmol. 2017 Jan 31;11:279-289
pubmed: 28203054
Int J Mol Sci. 2016 Jul 15;17(7):
pubmed: 27428965
Apoptosis. 2017 Jun;22(6):827-840
pubmed: 28315173
Cancers (Basel). 2020 Dec 11;12(12):
pubmed: 33322608
Melanoma Res. 2006 Jun;16(3):245-8
pubmed: 16718271
J Hematol Oncol. 2018 Sep 3;11(1):111
pubmed: 30176876
Blood. 2012 Mar 15;119(11):2579-89
pubmed: 22262760
Cancers (Basel). 2021 Jun 11;13(12):
pubmed: 34208068
Cancers (Basel). 2021 Feb 05;13(4):
pubmed: 33562653
Ocul Oncol Pathol. 2019 Apr;5(3):153-161
pubmed: 31049320
Intractable Rare Dis Res. 2016 Aug;5(3):185-91
pubmed: 27672541
Int J Mol Sci. 2017 Oct 21;18(10):
pubmed: 29065455
Adv Cancer Res. 2018;138:183-211
pubmed: 29551127
Genes Dev. 2019 Aug 1;33(15-16):983-1007
pubmed: 31123060
Biology (Basel). 2021 Mar 24;10(4):
pubmed: 33804830
Br J Ophthalmol. 2017 Jan;101(1):38-44
pubmed: 27574175
Exp Eye Res. 2003 Jun;76(6):653-61
pubmed: 12742347
Trans Am Ophthalmol Soc. 2016 Aug;114:T5
pubmed: 28018010
Aging (Albany NY). 2020 Dec 3;13(1):646-674
pubmed: 33293474
Clin Cancer Res. 2017 Jul 1;23(13):3307-3315
pubmed: 28053023
Cancers (Basel). 2020 Oct 13;12(10):
pubmed: 33066024
Int J Mol Sci. 2017 Jul 01;18(7):
pubmed: 28671573
Transl Oncol. 2019 Feb;12(2):350-360
pubmed: 30502589
Carcinogenesis. 2018 Jan 12;39(1):72-83
pubmed: 29106445
Pigment Cell Melanoma Res. 2008 Aug;21(4):457-63
pubmed: 18627530